Keyword: Eli Lilly

AstraZeneca is looking to boost its key inhaler with two outcomes-based deals with regional insurers.

Eli Lilly’s first oncology campaign launched last week, putting the drugmaker on a growing list of pharma companies running DTC ads for cancer drugs.

Merck and J&J presented numbers suggesting pharma faces increased pricing pressure, but one analyst is skeptical.

Drug materials are targets of U.S.-China trade war, analysts see more hope in the Takeda-Shire deal, China puts forward policies that favors generics over brands.

After Lilly’s Cyramza flopped a liver cancer trial in 2014, the company designed a trial for a specific subpopulation. Now, it’s back with a win.

Jockeying for market share, Eli Lilly offered more than half off its U.S. list prices in the form of rebates and discounts last year.

AbbVie scored a major reduction of damages in a retrial of an AndroGel liability case brought by plaintiff Jesse Mitchell.

Despite pharma resistance, investors are set to vote on resolutions seeking more information about how exec pay affects drug prices.

Former Eli Lilly CFO Derica Rice becomes the second top Big Pharma ex to take the reins at a major pharmacy benefit manager.

President Donald Trump Monday pledged to soon unveil a plan for drug prices and said the DOJ is considering suing opioid companies.